{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:42:21Z","timestamp":1770748941638,"version":"3.50.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,16]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Anti-melanoma differentiation-associated gene 5 (MDA-5) antibody-positive dermatomyositis (MDA5-DM) often causes rapidly progressive interstitial lung disease (RP-ILD). Although cancer complications in MDA5-DM are less frequently reported compared to other forms of DM, they do occur. For MDA5-DM patients with cancer, particularly in paraneoplastic settings, the primary treatment strategy often targets the malignancy first. However, surgery, chemotherapy, and radiotherapy carry significant risks of exacerbating ILD, especially in patients with respiratory failure. Despite improved prognosis with initial immunosuppressive combination therapy, some cases of MDA5-DM with RP-ILD remain refractory to treatment. Recent studies have shown the potential benefit of Janus kinase (JAK) inhibitors for refractory cases, though their impact on cancer progression remains a concern. We report a 48-year-old woman with MDA5-DM, RP-ILD, and bilateral breast cancer. Due to her respiratory condition, radical surgery and chemotherapy were initially not possible. Endocrine therapy and immunosuppressive therapy were administered, but the disease remained refractory. Tofacitinib, combined with plasma exchange, improved her ILD, allowing for bilateral mastectomy. One year later, MDA5 antibody titers became negative, and glucocorticoids were discontinued after two years. Three years later, neither MDA5-DM nor breast cancer has recurred. This is the first report of MDA5-DM complicated by breast cancer, and the first use of JAK inhibitors in such a case. Effective treatment requires close collaboration with oncologists to balance the risks and benefits of therapy in cases of MDA5-DM with RP-ILD and cancer.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae060","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T14:30:13Z","timestamp":1727447413000},"page":"93-99","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease complicated by bilateral breast cancer following the additional tofacitinib: A case report"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-5933","authenticated-orcid":false,"given":"Takashi","family":"Yamane","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Kakogawa Central City Hospital , Kakogawa, Hyogo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Kitayama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kakogawa Central City Hospital , Kakogawa, Hyogo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"2025011615464922900_R1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"2025011615464922900_R2","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025011615464922900_R3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir Med"},{"key":"2025011615464922900_R4","first-page":"373","article-title":"A systematic review and metaanalysis of predictors of mortality in idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"50","author":"Hannah","year":"2023","journal-title":"J Rheumatol"},{"key":"2025011615464922900_R5","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151959","article-title":"Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review","volume":"53","author":"McPherson","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2025011615464922900_R6","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"2025011615464922900_R7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7326\/0003-4819-84-1-68","article-title":"Dermatomyositis and malignancy. A review of the literature","volume":"84","author":"Barnes","year":"1976","journal-title":"Ann Intern Med"},{"key":"2025011615464922900_R8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/art.42311","article-title":"Subsets of idiopathic inflammatory myositis enriched for contemporaneous cancer relative to the general population","volume":"75","author":"Mecoli","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025011615464922900_R9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00296-022-05214-0","article-title":"Long-term risks of malignancy in myositis-specific antibody-positive idiopathic inflammatory myopathy","volume":"43","author":"Izuka","year":"2023","journal-title":"Rheumatol Int"},{"key":"2025011615464922900_R10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1095526","article-title":"Malignancies in systemic rheumatic diseases: a mini review","volume":"14","author":"Geng","year":"2023","journal-title":"Front Immunol"},{"key":"2025011615464922900_R11","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00296-019-04428-z","article-title":"Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study","volume":"39","author":"Motomura","year":"2019","journal-title":"Rheumatol Int"},{"key":"2025011615464922900_R12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021733","article-title":"Malignancy in dermatomyositis: a retrospective paired case-control study of 202 patients from Central China","volume":"99","author":"Chang","year":"2020","journal-title":"Medicine"},{"key":"2025011615464922900_R13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025011615464922900_R14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s12282-023-01505-x","article-title":"The Japanese Breast Cancer Society Clinical Practice guidelines for systemic treatment of breast cancer, 2022 edition","volume":"30","author":"Terada","year":"2023","journal-title":"Breast Cancer"},{"key":"2025011615464922900_R15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-010-1057-y","article-title":"Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics","volume":"126","author":"Kheirelseid","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2025011615464922900_R16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2325\/jbcs.14.277","article-title":"Clinicopathologic significance of an immunohistochemical expression of p27 in scirrhous carcinoma of the breast","volume":"14","author":"Nozoe","year":"2007","journal-title":"Breast Cancer"},{"key":"2025011615464922900_R17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021899","article-title":"Clinical characteristics and prognostic analysis of Chinese dermatomyositis patients with malignancies","volume":"99","author":"Shao","year":"2020","journal-title":"Medicine"},{"key":"2025011615464922900_R18","doi-asserted-by":"crossref","first-page":"13086","DOI":"10.1002\/cam4.5989","article-title":"Survival in elderly patients with breast cancer with and without autoimmune disease","volume":"12","author":"Dedousis","year":"2023","journal-title":"Cancer Med"},{"key":"2025011615464922900_R19","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2444-5","article-title":"Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis","volume":"16","author":"Park","year":"2016","journal-title":"BMC Cancer"},{"key":"2025011615464922900_R20","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.3747\/co.24.3696","article-title":"Breast cancer and dermatomyositis: a case study and literature review","volume":"24","author":"Hendren","year":"2017","journal-title":"Curr Oncol"},{"key":"2025011615464922900_R21","doi-asserted-by":"crossref","DOI":"10.1093\/jscr\/rjv075","article-title":"Dermatomyositis presenting as a paraneoplastic syndrome with resolution of symptoms following surgical management of underlying breast malignancy","volume":"2015","author":"Luu","year":"2015","journal-title":"J Surg Case Rep"},{"key":"2025011615464922900_R22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/CMAR.S349400","article-title":"Triple-negative breast cancer with dermatomyositis: a case report and literature review","volume":"14","author":"Chen","year":"2022","journal-title":"Cancer Manag Res"},{"key":"2025011615464922900_R23","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.10.2010.3416","article-title":"Dermatomyositis presenting as a paraneoplastic syndrome due to underlying breast cancer","volume":"2011","author":"Sandhu","year":"2011","journal-title":"BMJ Case Rep"},{"key":"2025011615464922900_R24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clbc.2021.05.014","article-title":"A review of treatment-induced pulmonary toxicity in breast cancer","volume":"22","author":"Mo","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"2025011615464922900_R25","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"2025011615464922900_R26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000314265","article-title":"Dermatosis as the initial manifestation of malignant breast tumors: retrospective analysis of 4 cases","volume":"5","author":"Song","year":"2010","journal-title":"Breast Care"},{"key":"2025011615464922900_R27","article-title":"Predictors of postoperative acute exacerbation of interstitial lung disease: a case-control study","volume":"7","author":"Hosoki","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"2025011615464922900_R28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.radonc.2019.03.006","article-title":"Toxicity after radiotherapy in patients with historically accepted contraindications to treatment (CONTRAD): An international systematic review and meta-analysis","volume":"135","author":"Lin","year":"2019","journal-title":"Radiother Oncol"},{"key":"2025011615464922900_R29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0167-8140(02)00136-6","article-title":"Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients","volume":"64","author":"Koc","year":"2002","journal-title":"Radiother Oncol"},{"key":"2025011615464922900_R30","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1177\/10781552221084058","article-title":"Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: a case report","volume":"28","author":"Villalba-Cuesta","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"2025011615464922900_R31","article-title":"A rare case of severe myositis as paraneoplastic syndrome on breast cancer","volume":"13","author":"Novais Dias","year":"2015","journal-title":"World J Surg Oncol"},{"key":"2025011615464922900_R32","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3390\/curroncol28030182","article-title":"A case of pathological complete response and resolution of dermatomyositis following neoadjuvant chemotherapy in HER2-positive early breast cancer","volume":"28","author":"Piras","year":"2021","journal-title":"Curr Oncol"},{"key":"2025011615464922900_R33","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025011615464922900_R34","first-page":"51","article-title":"Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: Successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy","volume":"20","author":"Ichiyasu","year":"2016","journal-title":"Respir Med Case Rep"},{"key":"2025011615464922900_R35","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1684\/ejd.2014.2381","article-title":"Anti-MDA5 antibody-positive dermatomyositis with lethal progressive interstitial lung disease and advanced gastric cancer","volume":"24","author":"Yamaoka","year":"2014","journal-title":"Eur J Dermatol"},{"key":"2025011615464922900_R36","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/ced.12674","article-title":"Amyophatic dermatomyositis presenting as a flagellated skin eruption with positive MDA5 antibodies and thyroid cancer: a real association?","volume":"40","author":"Molina-Ruiz","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"2025011615464922900_R37","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3106","article-title":"Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study","volume":"14","author":"S\u00f8rensen","year":"2012","journal-title":"Breast Cancer Res"},{"key":"2025011615464922900_R38","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/annonc\/mdu453","article-title":"Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study","volume":"25","author":"Lietzen","year":"2014","journal-title":"Ann Oncol"},{"key":"2025011615464922900_R39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12282-016-0666-7","article-title":"Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer","volume":"24","author":"Nakatsukasa","year":"2017","journal-title":"Breast Cancer"},{"key":"2025011615464922900_R40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(87)92744-9","article-title":"Risk of therapy-related leukaemia and preleukaemia after Hodgkin\u2019s disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy","volume":"2","author":"Pedersen-Bjergaard","year":"1987","journal-title":"Lancet"},{"key":"2025011615464922900_R41","first-page":"100","article-title":"Malignancies in Wegener\u2019s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou","year":"2008","journal-title":"J Rheumatol"},{"key":"2025011615464922900_R42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.21037\/tau-22-138","article-title":"Carcinogenicity risk associated with tacrolimus use in kidney transplant recipients: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2022","journal-title":"Transl Androl Urol"},{"key":"2025011615464922900_R43","doi-asserted-by":"crossref","first-page":"677","DOI":"10.12659\/AOT.904417","article-title":"tacrolimus levels are not associated with risk of malignancy in lung transplant recipients","volume":"22","author":"Fox","year":"2017","journal-title":"Ann Transplant"},{"key":"2025011615464922900_R44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00228-017-2234-2","article-title":"The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation","volume":"73","author":"Lichtenberg","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2025011615464922900_R45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025011615464922900_R46","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57121358","article-title":"Combination therapy with rituximab, tofacitinib and pirfenidone in a patient with rapid progressive interstitial lung disease (RP-ILD) due to MDA5 antibody-associated dermatomyositis: a case report","volume":"57","author":"Yen","year":"2021","journal-title":"Medicina"},{"key":"2025011615464922900_R47","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021943","article-title":"Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report","volume":"99","author":"Ishikawa","year":"2020","journal-title":"Medicine"},{"key":"2025011615464922900_R48","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114760","article-title":"Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential","volume":"193","author":"Tzeng","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"2025011615464922900_R49","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1002\/jcp.29593","article-title":"Janus kinase inhibitors: a therapeutic strategy for cancer and autoimmune diseases","volume":"235","author":"Hosseini","year":"2020","journal-title":"J Cell Physiol"},{"key":"2025011615464922900_R50","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00296-024-05551-2","article-title":"Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease","volume":"44","author":"Harada","year":"2024","journal-title":"Rheumatol Int"},{"key":"2025011615464922900_R51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2025011615464922900_R52","first-page":"291","article-title":"Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis","volume":"41","author":"Shirai","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025011615464922900_R53","article-title":"Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solipuram","year":"2021","journal-title":"Auto Immun Highlights"},{"key":"2025011615464922900_R54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025011615464922900_R55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025011615464922900_R56","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"27","author":"Fleury","year":"2016","journal-title":"Ann Oncol"},{"key":"2025011615464922900_R57","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025011615464922900_R58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/03009742.2021.1995984","article-title":"Efficacy and safety of plasma exchange in interstitial lung diseases with anti-melanoma differentiation-associated 5 gene antibody positive clinically amyopathic dermatomyositis","volume":"52","author":"Komai","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"2025011615464922900_R59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845988","article-title":"Different multivariable risk factors for rapid progressive interstitial lung disease in Anti-MDA5 positive dermatomyositis and anti-synthetase syndrome","volume":"13","author":"Zuo","year":"2022","journal-title":"Front Immunol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae060\/59811862\/rxae060.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/1\/93\/59811862\/rxae060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/1\/93\/59811862\/rxae060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T15:53:12Z","timestamp":1737042792000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/9\/1\/93\/7780343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,9,27]]},"published-print":{"date-parts":[[2025,1,16]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae060","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,9,27]]}}}